The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-10 and is reviewed periodically as new material appears.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
=== Prenatal and newborn screening === Checking for hemoglobinopathies begins during pregnancy, with a prenatal screening questionnaire which includes, among other things, a consideration of health issues in the child's parents and close relatives. During pregnancy, genetic testing can be done on samples taken of fetal blood, of amniotic fluid, or chorionic villus sampling. A routine heel prick test, in which a small sample of blood is collected a few days after birth, can detect some forms of hemoglobinopathy.
dosage compensation Any mechanism by which organisms neutralize the large difference in gene dosage caused by the presence of differing numbers of sex chromosomes in the different sexes, thereby equalizing the expression of sex-linked genes so that the members of each sex receive the same or similar amounts of the products of such genes. An example is X-inactivation in female mammals.
== Properties == LCRs are more abundant in eukaryotes, but they also have a significant presence in many prokaryotes. On average, 0.05 and 0.07% of the bacterial and archaeal proteomes (total amino acids of LCRs in a given proteome/total amino acids of that proteome) form LCRs whereas for five model eukaryotic proteomes (human, fruitfly, yeast, fission yeast, Arabidopsis) this coverage was significantly higher (on average, 0.4%; between 2 and 23 times higher than prokaryotes). Eukaryotic LCRs tend to be longer than prokaryotic LCRs. The average size of a eukaryotic LCR is 42 amino acids long, whereas bacterial, archaeal and phage LCRs are 38, 36 and 33 amino acids long, respectively. In the Archaea, the halobacterium Natrialba magadii has the highest number of LCRs and the highest enrichment for LCRs. In Bacteria, Enhygromyxa salina, a delta proteobacterium that belongs to myxobacteria has the highest number of LCRs and the highest enrichment for LCRs. Intriguingly, four of the top five bacteria with the highest enrichment for LCRs are also myxobacteria. The three most enriched amino acids within LCRs of Bacteria are proline, glycine and alanine, whereas in Archaea they are threonine, aspartate and proline. In Phages, they are alanine, glycine and proline. Glycine and proline emerge as very enriched amino acids in all three evolutionary lineages, whereas alanine is highly enriched in Bacteria and Phages but not enriched in Archaea.
=== 1995 leadership election === John Major was consistently opposed by Eurosceptics in his party (known as the Maastricht Rebels – a small minority of MPs before 1997, but enjoying much wider support among party activists). Heseltine always stated categorically that he would never stand for party leader against Major. In mid-1995 Major challenged his critics to "put up or shut up" by resubmitting himself to a leadership election in which he was unsuccessfully opposed by John Redwood the Secretary of State for Wales. There was speculation that Heseltine's supporters would engineer Major's downfall in the hope that their man would take over, but they stayed loyal to Major. Heseltine had been listening to regular reports about his potential support from his lieutenants Keith Hampson, Richard Ottaway, Michael Mates and Peter Temple-Morris, and in the event of a second ballot hoped to receive Major's endorsement. Peter Tapsell refused to support him because of the European issue. Hampson believed that Heseltine might have won, as did Philip Stephens of the Financial Times. Michael Crick does not agree, pointing out that many of Heseltine's supporters from 1990 had retired from the Commons and the 1992 intake was more right-wing and eurosceptic. Heseltine, who showed his ballot paper to the returning officers to prove that he had voted for Major, commented that "John Major deserves a great deal better than that from his colleagues". Major was re-elected leader.
== External links == HPRD Human Protein Reference Database, a (manually) curated database of human protein information with visualization tools IntAct Interaction Database, a public repository for manually curated molecular interaction data from the literature DIP Database of Interacting Proteins, a manual and automatic catalog of experimentally determined interactions between proteins MIPS Mammalian Protein–Protein Interaction Database, the MIPS mammalian protein–protein interaction database
Sources: en.wikipedia.org
The New York Times described Harris's economic policy as embracing "the idea that the federal government must act aggressively to foster competition and correct distortions in private markets". Harris proposed raising taxes on corporations and high-earners to fund services for the lower and middle classes and reduce the deficit. Harris stated she supported increasing the top tier capital gains tax rate to 28%, up from 20% and lower than Biden's proposed 39.6%. Harris stated her support for a Billionaire Minimum Income Tax, increasing the tax on stock buybacks to 4%, and a ten-fold tax reduction for small business ranging from $5,000 to $50,000 in relief. Harris also supported efforts to create a tax on unrealized gains for those with more than a $100 million in net worth if they do not pay a minimum 25% tax rate on their income inclusive of unrealized gains so long as 80% of said wealth is in tradeable assets. The plan would impact a small percentage of the wealthy in the United States, and Axios reported most tech founders and investors would be spared. Harris also announced support for restoring the corporate tax rate to 28% among several other tax proposals to raise taxes and close loopholes for corporations and the wealthy that would bring in $5 trillion in additional revenue over 10 years. Harris proposed tax breaks to companies delivering economic benefit, such as manufacturing technologies that mitigate climate change and building affordable housing, and proposed a ban on corporate price gouging to "help the food industry become more competitive".
=== EC 1.12.1 With NAD+ or NADP+ as acceptor === EC 1.12.1.1: Now EC 1.12.7.2, ferredoxin hydrogenase EC 1.12.1.2: hydrogen dehydrogenase EC 1.12.1.3: hydrogen dehydrogenase (NADP+) EC 1.12.1.4: hydrogenase (NAD+, ferredoxin) EC 1.12.1.5: hydrogen dehydrogenase [NAD(P)+]
120 g acetic acid (60 g/mol, 2.0 mol) was reacted with 230 g ethanol (46 g/mol, 5.0 mol), yielding 132 g ethyl acetate (88 g/mol, 1.5 mol). The yield was 75%. The molar amount of the reactants is calculated from the weights (acetic acid: 120 g ÷ 60 g/mol = 2.0 mol; ethanol: 230 g ÷ 46 g/mol = 5.0 mol). Ethanol is used in a 2.5-fold excess (5.0 mol ÷ 2.0 mol). The theoretical molar yield is 2.0 mol (the molar amount of the limiting compound, acetic acid). The molar yield of the product is calculated from its weight (132 g ÷ 88 g/mol = 1.5 mol). The % yield is calculated from the actual molar yield and the theoretical molar yield (1.5 mol ÷ 2.0 mol × 100% = 75%).
== Applications == Research into the AMP family—particularly in regards to their mechanism of action—has been ongoing for nearly 20 years. Despite sustained interest, treatments derived or utilizing AMPs have not been widely adopted for clinical use for several reasons. One, drug candidates from AMPs have a narrow window of bioavailability, because peptides are quickly broken down by proteases. Two, peptide drugs are more expensive than small molecule drugs to produce, which is problematic since peptide drugs must be given in large doses to counter rapid enzymatic breakdown. These qualities also limit routes of administration, typically to injection, infusion, or slow release therapy. Research into new and improved variations derived from cathelicidin continues.
Sources: en.wikipedia.org
=== Breakthrough in talks === On the evening of 8 October 1972, at a secret meeting of Kissinger and Tho in a house in the Paris suburb of Gif-sur-Yvette once owned by the painter Fernand Léger, the decisive breakthrough in the talks came. Tho believed that Kissinger was, as he later put it, "in a rush" for a peace deal before the presidential election, and began with what he called "a very realistic and very simple proposal" for a ceasefire that would see the Americans pull all their forces out of Vietnam in exchange for the release of all the POWs in North Vietnam. As for the ultimate fate of South Vietnam, Tho proposed the creation of a "council of national reconciliation" that would govern the nation, but in the meantime, Thiệu could stay in power until the council was formed, while a "leopard's spot" ceasefire would come into effect with the Viet Cong and the Saigon government controlling whatever territories they were had at the time of the ceasefire. The "mutual withdrawal formula" was to be disregarded, with PAVN forces to stay in South Vietnam, with Tho giving Kissinger a vague promise that no more supplies would be sent down the Ho Chi Minh Trail. Kissinger accepted Tho's offer as the best deal possible, saying that the "mutual withdrawal formula" had to be abandoned, as it had been "unobtainable through ten years of war...We could not make it a condition for a final settlement. We had long passed that threshold".
By 1987, companies selling lasers were claiming that they could treat pain, accelerate healing of sports injuries, and treat arthritis, but there was little evidence for this at that time. Mester originally called this approach "laser biostimulation", but it soon became known as "low-level laser therapy". With the adaptation of light emitting diodes it became known as "low-level light therapy"; to resolve confusion around the exact meaning of "low level", the term "photobiomodulation" arose as a synonym.
==== Inclusion of plasticizers ==== Inclusion of plasticizers tends to lower Tg and increase polymer flexibility. Addition of the plasticizer will also modify dependence of the glass-transition temperature Tg on the cooling rate. The mobility of the chain can further change if the molecules of plasticizer give rise to hydrogen bonding formation. Plasticizers are generally small molecules that are chemically similar to the polymer and create gaps between polymer chains for greater mobility and fewer interchain interactions. A good example of the action of plasticizers is related to polyvinylchlorides or PVCs. A uPVC, or unplasticized polyvinylchloride, is used for things such as pipes. A pipe has no plasticizers in it, because it needs to remain strong and heat-resistant. Plasticized PVC is used in clothing for a flexible quality. Plasticizers are also put in some types of cling film to make the polymer more flexible.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
不是。Semax 是完全人工合成的七肽，自然界中没有对应的已知肽段。它的设计灵感来自促肾上腺皮质激素片段 ACTH(4-10)，但序列经过了替换和延长。